A multicenter phase I/II study of donor CD19-directed CAR-transduced Epstein–Barr virus (EBV)-specific cytotoxic T lymphocytes (CTLs) in pediatric patients with acute ALL showed that the use of donor EBV-specific CTLs to manufacture CD19CAR could enhance the CAR-T cell expansion/persistence after vaccination with EBV-specific peptides (121). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.